Side-by-side · Research reference
SemaglutidevsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedFlagship15/53 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
Semaglutide
Vilon
Primary target
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Immune cell differentiation pathways, chromatin modification
Pathway
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
Unknown — no HPA/HPG axis data
Origin
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
—
—
02Dosage Protocols
Parameter
Semaglutide
Vilon
Standard dose (weight, Wegovy)
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
—
Frequency
Once weekly, same day each week
Unknown — literature does not specify chronic administration protocols
Titration schedule
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Mouse / in vitro only
Duration
Indefinite for chronic indication
Discontinuation results in weight regain.
Not characterised in humans
Reconstitution
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
—
Timing
Any time of day, with or without food
—
Half-life
~7 days (168 h)WEGOVY (semaglutide) injection 2021
Not published — dipeptides typically <10 min plasma t½
Standard dose
—
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Route
—
Likely SQ or oral (Khavinson school uses both); no published ROA validation
04Side Effects & Safety
Parameter
Semaglutide
Vilon
Injection site reaction
Mild erythema, pruritus
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
—
Hypoglycemia
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
—
Gallbladder events
Increased cholelithiasis
—
Heart rate
Modest ↑ resting HR (~2-4 bpm)
—
Human safety data
—
Absent from PubMed-indexed literature
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formation
—
Not reported; dipeptides generally low immunogenicity
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
Semaglutide
Vilon
1. Reconstitution / device
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Timing
Once weekly, same day. Day can be changed if ≥2 days separate doses.
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Storage
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
5. Needle
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
—
06Stack Synergy
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation